Literature DB >> 14753382

Vaccine safety.

Robert M Jacobson1.   

Abstract

Rates of reported adverse events are remarkably low. VAERS identifies an adverse event rate approximating 11.4 reports per 100,000 vaccine doses. Approximately 15% of these reports represent SAEs, but less than 2% involve death; in most cases, reviews have shown no causal relation between the events and the vaccine. Across the spectrum of vaccines in use (including those directed against influenza and hepatitis B virus), many claims of adverse events regarding vaccines represent typical reactions to vaccinations. These reactions can be thought of as foreign-body reactions and predominate among the inactivated vaccines. In controlled studies, the adverse event rates that occur with vaccination resemble those that occur with placebo injections. Typical reactions associated with live viral and bacterial vaccines, such as MMR and varicella vaccines, may resemble attenuated forms of the disease for which the vaccine is directed. Other claims against vaccines represent chance-coincidence or misunderstood data; further studies of claims have vindicated the overall safety of the vaccines in most cases. Two documented safety concerns with vaccines, however, have demonstrated that vaccines (like other biologics and pharmacologic) can result in harm (eg, rotavirus and OPV vaccines). The denouement with these vaccines indicates the broad postmarketing data collection and evaluation that extends efforts made with prelicensure study to balance the benefits from vaccination with the risk for harm. Overall, measures including prelicensure study and postlicensure surveillance, such as VAERS, the Vaccine Safety Datalink Project, and the Clinical Immunization Safety Assessment Centers, have resulted in an exceptional safety profile for the vaccines in use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14753382     DOI: 10.1016/s0889-8561(03)00090-0

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  4 in total

Review 1.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

Review 2.  Update on side effects from common vaccines.

Authors:  Benjamin J Song; Rohit K Katial
Journal:  Curr Allergy Asthma Rep       Date:  2004-11       Impact factor: 4.919

3.  Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade.

Authors:  Lise Aagaard; Erik Wind Hansen; Ebba Holme Hansen
Journal:  Eur J Clin Pharmacol       Date:  2010-11-16       Impact factor: 3.064

4.  Compulsory and recommended vaccination in Italy: evaluation of coverage and non-compliance between 1998-2002 in Northern Italy.

Authors:  Serena Stampi; Rita Ricci; Isa Ruffilli; Franca Zanetti
Journal:  BMC Public Health       Date:  2005-04-21       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.